Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RETRACTED ARTICLE: The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
Mahmoud S. Abdallah, Esraa M. Mosalam, Abdel‐Aziz A. Zidan, et al.
Neurotherapeutics (2020) Vol. 17, Iss. 4, pp. 1897-1906
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 83
Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?
Moein Ala, Mahan Ala
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 6, pp. 1747-1770
Open Access | Times Cited: 64
Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders
Nuojin Li, Tian Zhou, Erkang Fei
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8281-8281
Open Access | Times Cited: 41
Comparing the effect of fluoxetine, escitalopram, and sertraline, on the level of BDNF and depression in preclinical and clinical studies: a systematic review
Nastaran Talaee, Shataw Azadvar, Sanaz Khodadadi, et al.
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 7, pp. 983-1016
Closed Access | Times Cited: 9
Pathophysiology linking depression and type 2 diabetes: Psychotherapy, physical exercise, and fecal microbiome transplantation as damage control
Rhea Subba, Rajat Sandhir, Surya Pratap Singh, et al.
European Journal of Neuroscience (2021) Vol. 53, Iss. 8, pp. 2870-2900
Closed Access | Times Cited: 45
Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial
Atefeh Zandifar, Maryam Panahi, Rahim Badrfam, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study
Lars Vedel Kessing, Helene C. W. Rytgaard, Claus Thorn Ekstrøm, et al.
Diabetes Care (2020) Vol. 43, Iss. 12, pp. 3050-3060
Open Access | Times Cited: 49
Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial
Tavgah Ahmed Merza Mohammad, Talar Ahmed Merza Mohammad, Teshk Shawis
Brain Research Bulletin (2024) Vol. 216, pp. 111047-111047
Open Access | Times Cited: 5
The role of metformin as a treatment for neuropsychiatric illness
Seetal Dodd, Luba Sominsky, Dan Siskind, et al.
European Neuropsychopharmacology (2022) Vol. 64, pp. 32-43
Closed Access | Times Cited: 21
Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder
Wenjun Su, Ting Hu, Chun‐Lei Jiang
Current Neuropharmacology (2023) Vol. 22, Iss. 5, pp. 810-842
Closed Access | Times Cited: 12
Mechanisms affecting brain remodeling in depression: do all roads lead to impaired fibrinolysis?
Silvia Hoirisch-Clapauch
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 525-533
Closed Access | Times Cited: 23
Association of metformin and depression in patients with type 2 diabetes
Huan Yu, Ruotong Yang, Junhui Wu, et al.
Journal of Affective Disorders (2022) Vol. 318, pp. 380-385
Closed Access | Times Cited: 15
Efficacy and Safety of Antidiabetic Agents for Major Depressive Disorder and Bipolar Depression: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Jian Zhang, Rongyi Sun, Yang Cai, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1172-1172
Open Access | Times Cited: 3
Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence
Brett D. M. Jones, Salman Farooqui, Stefan Kloiber, et al.
Life (2021) Vol. 11, Iss. 8, pp. 819-819
Open Access | Times Cited: 20
Agmatine as a novel candidate for rapid-onset antidepressant response
Ana Paula Valverde, Anderson Camargo, Ana Lúcia S. Rodrigues
World Journal of Psychiatry (2021) Vol. 11, Iss. 11, pp. 981-996
Open Access | Times Cited: 20
The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial
Mahmoud S. Abdallah, Sumaiah J. Alarfaj, Dalia S. Saif, et al.
International Immunopharmacology (2021) Vol. 95, pp. 107575-107575
Closed Access | Times Cited: 18
Metformin for the Improvement of Comorbid Depression Symptoms in Diabetic Patients: A Systematic Review
Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, et al.
Cureus (2022)
Open Access | Times Cited: 13
Metformin improves depressive-like symptoms in mice via inhibition of peripheral and central NF-κB-NLRP3 inflammation activation
Ren-Wei Du, Wen-Guang Bu
Experimental Brain Research (2020) Vol. 238, Iss. 11, pp. 2549-2556
Closed Access | Times Cited: 20
RETRACTED: Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
Mahmoud S. Abdallah, Ahmed Nabil Ramadan, Hend Omara‐Reda, et al.
CNS Neuroscience & Therapeutics (2021) Vol. 27, Iss. 12, pp. 1540-1548
Open Access | Times Cited: 17
Diabetes and mood disorders: shared mechanisms and therapeutic opportunities
Laís Bhering Martins, Jenneffer Rayane Braga Tibães, Michael Berk, et al.
International Journal of Psychiatry in Clinical Practice (2021) Vol. 26, Iss. 2, pp. 183-195
Closed Access | Times Cited: 16
Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities
Antônio Lúcio Teixeira, Laís Bhering Martins, Michael Berk, et al.
Clinical Science (2022) Vol. 136, Iss. 17, pp. 1257-1280
Closed Access | Times Cited: 12
Metformin Ameliorates Lipopolysaccharide-Induced Depressive-Like Behaviors and Abnormal Glutamatergic Transmission
Chen Jiang, Tian Zhou, Amin Guo, et al.
Biology (2020) Vol. 9, Iss. 11, pp. 359-359
Open Access | Times Cited: 17
Chronotherapeutic neuroprotective effect of verapamil against lipopolysaccharide-induced neuroinflammation in mice through modulation of calcium-dependent genes
Esraa M. Mosalam, Aya Ibrahim Elberri, Amany Said Sallam, et al.
Molecular Medicine (2022) Vol. 28, Iss. 1
Open Access | Times Cited: 11
The Role of the Adrenal–Gut–Brain Axis on Comorbid Depressive Disorder Development in Diabetes
Thalita Mázala-de-Oliveira, Bruna Silva, Paula Campello‐Costa, et al.
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1504-1504
Open Access | Times Cited: 6
Metformin Enhances Excitatory Synaptic Transmission onto Hippocampal CA1 Pyramidal Neurons
Wenbing Chen, Jiang Chen, Ziyang Liu, et al.
Brain Sciences (2020) Vol. 10, Iss. 10, pp. 706-706
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top